U.S. Food and Drug Administration staff reviewers said on Tuesday data demonstrating an immune response to Moderna's flu ...
The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...
Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA ...
The Food and Drug Administration (FDA) is getting ready to evaluate Moderna’s messenger RNA-based flu shot, MFLUSIVA, Fierce ...
During her presentation, Moderna’s Das said the company proposed a “modified regulatory framework” during the FDA meeting.
By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. FDA are meeting on Thursday to evaluate Moderna ...
By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed ...
Presented by Philip Morris International{beacon} View Online Health Care Health Care PRESENTED BY The Big Story FDA panel set ...
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...
No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results